You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Cochlear Ltd (ASX:COH) has experienced a sharp pullback across multiple timeframes, prompting investors to reassess the outlook for the hearing implant manufacturer. The stock is currently trading around AUD 200.75, down 0.77% for the day, but significantly lower over longer periods.
Shares of Clarity Pharmaceuticals Ltd (ASX:CU6) climbed 17.48% to AUD 3.36 at the time of writing on 16 February 2026, marking a daily gain of AUD 0.50. The rally extended the stock’s five-day advance to 13.90%, reflecting renewed investor activity following recent clinical developments.
AVITA Medical Inc (ASX:AVH) shares traded flat at AUD 1.09 during the afternoon session on 13 February 2026, closing in line with the previous session following the release of its Q4 FY25 and full-year FY25 results. Over the past one year, the stock has …
Cochlear Limited (ASX:COH) reported lower first-half earnings for FY26, with profit impacted by contracting delays for its newly launched implant system and one-off expenses. Shares fell 14.72% to AUD 209.47 by 10:47am on 13 February 2026. Despite the decline,brokersJefferies and Canaccord Genuity have issued …
Neuren Pharmaceuticals Ltd. (ASX:NEU) has experienced notable fluctuations in its share performance, reflecting market volatility and investor focus on the company’s ongoing operations and strategic initiatives. The stock has seen periods of both short-term recovery and longer-term adjustments, drawing attention to market sentiment and …
Pro Medicus Ltd (ASX:PME) shares fell 15.68% to AUD 141.37 on 12 February following the release of its half-year results. The stock is now down 36.50% year-to-date and 50.97% over the past 12 months.
CSL Ltd (ASX:CSL) has seen a significant decline over multiple time frames, reflecting prolonged market pressures. On 11 February 2026, shares closed at AUD 160.59, down 6.30% for the day. Over the past month, shares fell 8.29%, and six-month losses reached 39.13%. Year-to-date decline …
Pro Medicus Ltd (ASX:PME) is experiencing notable fluctuations in its share price, currently trading at AUD 164.22. Over the past month, the stock has dropped 23.03%, while year-to-date performance shows a decline of 26.24%. Despite these declines, the six-month performance reflects a 46.12% increase. …
ASX-listed biotechnology stocks have returned to the spotlight after global investment firm Jefferies issued Buy ratings on three Australian pharmaceutical companies—Mesoblast Ltd, Telix Pharmaceuticals Ltd and Clarity Pharmaceuticals Ltd. Despite recent share price declines across the sector, Jefferies’ latest assessments highlight upside potential driven …